OncoSenX is a late stage pre-clinical cancer company which focuses on genetic information to discover the next generation of cancer therapy. It targets solid tumors based on transcriptional activity using a lipid nanoparticle and plasmid DNA. The company offers a less invasive, more precise intervention approach.
|Employees (est.) (Jan 2022)||12||(+10%)|
OncoSenX total Funding
OncoSenX latest funding size
Time since last funding
|3 years ago|
Who are OncoSenX key executives?
OncoSenX's key executives are Matthew Scholz, John D. Lewis and Gary C. Hudson.
How many employees does OncoSenX have?
OncoSenX has 12 employees.
Who are OncoSenX competitors?
Competitors of OncoSenX include Strata Oncology, LXRepair and Serotiny.
Receive alerts for 300+ data fields across thousands of companies